• January 29, 2014
    PARIS, FRANCE, January 29, 2014 – Zoetis Inc. announced today the launch of Apoquel® (oclacitinib maleate), a novel therapy indicated for the treatment of pruritus (itching) associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis. Veterinarians across Europe now have a first-in-class treatment choice that targets the itch of allergic skin conditions in dogs.Apoquel is the first Janus Kinase (JAK) inhibitor approved for veterinary use. It provides rapidmore...
  • October 1, 2013
    FLORHAM PARK, N.J., October 1, 2013 – Zoetis Inc., (NYSE: ZTS) formerly the animal health business unit of Pfizer Inc., has notified the U.S. Food and Drug Administration (FDA) that the company will voluntarily withdraw the marketing authorizations (New Animal Drug Applications) for 3-Nitro (roxarsone)  and Carb-O-Sep ® (carbarsone). The decision to withdraw the marketing authorization for 3-Nitro, a feed medicine containing the organic arsenical roxarsone, follows the suspension ofmore...
  • August 4, 2013
    HUINAN, JILIN, China--(BUSINESS WIRE)--Zoetis today announced that its joint venture in China received the approval by the Ministry of Agriculture of the People’s Republic of China for Rui Lan An™, a specialized vaccine to help control the highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). Rui Lan An, which will be launched later this month, is the first vaccine to emerge from the joint venture that was established to develop and manufacture animal vaccinesmore...
  • July 8, 2013
    FLORHAM PARK, N.J., July 8, 2013 – U.S. pork producers and the packers that harvest the meat they produce now have the added assurance that the U.S. Department of Agriculture (USDA) has approved two processes regarding the use of IMPROVEST® (gonadotropin releasing factor analog – diphtheria toxoid conjugate).  IMPROVEST, an immunological product, is approved by the U.S. Food and Drug Administration (FDA) for the temporary immunological castration and reduction of boar taint* in intactmore...
  • June 6, 2013
    BANGKOK, THAILAND - Zoetis Inc., formerly the animal health business unit of Pfizer Inc., is organizing a Congress with more than  1,000 animal health industry professionals to map out a strategy that will put Thailand in the forefront of  ASEAN’s animal health sector.  Professionals involved in veterinary science, including academics, veterinarians, farm owners, professionals in the livestock sector, as well as technicians and manufacturers of equipment related to animal healthmore...
  • May 16, 2013
    MADISON, N.J.--(BUSINESS WIRE)--Zoetis, Inc. (NYSE: ZTS), formerly the animal health business unit of Pfizer Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved APOQUEL® (oclacitinib tablet) for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. Pruritus, or itching, is the most common sign of allergies in dogs. Developed by Zoetis, APOQUEL is the first Janus kinase (JAK)more...
  • April 15, 2013
    ZoetisTM, formerly the animal health business unit of Pfizer Inc., today announced the U.S. Department of Agriculture (USDA) has approved a newly-enhanced version of the WITNESS® HW Heartworm Antigen Test kit for dogs and cats. Launched today, the enhanced WITNESS HW test kit is now available to veterinarians nationwide. Enhancements to the biologics, including test antibodies, improvements to the buffer and sample pad and improve themore...
  • November 1, 2012
    Australian horse owners who are battling against the deadly Hendra virus received an important boost today with the introduction of Equivac® HeV vaccine. The Equivac® HeV vaccine will be available for use under permit by accredited veterinarians thanks to an international public-private partnership created to make this important new vaccine accessible. The vaccine, launched by Pfizer Animal Health, will help prevent the spread of the Hendramore...
  • October 3, 2012
    Pfizer Animal Health announces the launch of Poulvac E coli, the first spray vaccine against avian pathogenic Escherichia coli (APEC) for the poultry industry to be approved in the European Union. This new vaccine is based on a European E. coli isolate, and has been shown to provide a broad protection against field infections found in the region. It can be administered from one day of age, and studies have shown that it generates amore...
  • July 25, 2012
    VANCOUVER, British Columbia--Pfizer Animal Health will present data from discovery studies validating specific pathways of allergic skin disease in dogs and studies evaluating novel molecules targeting these pathways at the 7th World Congress of Veterinary Dermatology (WCVD) Meeting 2012 in Vancouver, British Columbia, from July 24–28. Approximately six presentations related to Pfizer’s research and development program in veterinary dermatologymore...